Erratum: Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53 (DOI:10.1016/j.ccr.2009.11.025);Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53

Cancer Cell

Volumn 17, Issue 3, 2010, Pages 273-285

  Stambolsky, Perry ^a   Tabach, Yuval ^a   Fontemaggi, Giulia ^b   Weisz, Lilach ^a   Maor Aloni, Revital ^a   Sigfried, Zahava ^c   Shiff, Idit ^c   Kogan, Ira ^a   Shay, Moshe ^a   Kalo, Eyal ^a   Blandino, Giovanni ^a   Simon, Itamar ^c   Oren, Moshe ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

CELLCYCLE

Indexed keywords

COLECALCIFEROL; PROTEIN P53; VITAMIN D;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; GENE ACTIVATION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; TRANSACTIVATION; TRANSCRIPTION REGULATION; VITAMIN D METABOLISM;

EID: 77649298024     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.04.017     Document Type: Erratum

References (54)

1. Acevedo V.D., Gangula R.D., Freeman K.W., Li R., Zhang Y., Wang F., Ayala G.E., Peterson L.E., Ittmann M., and Spencer D.M. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12 (2007) 559-571
2. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., and Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89 (1997) 1175-1184
3. Billiet L., Furman C., Larigauderie G., Copin C., Page S., Fruchart J.C., Brand K., and Rouis M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J. Cell. Physiol. 214 (2008) 183-191
4. Bossi G., Lapi E., Strano S., Rinaldo C., Blandino G., and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25 (2006) 304-309
5. Colston K.W., Chander S.K., Mackay A.G., and Coombes R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 44 (1992) 693-702
6. Deeb K.K., Trump D.L., and Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7 (2007) 684-700
7. Di Agostino S., Strano S., Emiliozzi V., Zerbini V., Mottolese M., Sacchi A., Blandino G., and Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10 (2006) 191-202
8. Duque G., El Abdaimi K., Henderson J.E., Lomri A., and Kremer R. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 35 (2004) 57-64
9. Elkon R., Linhart C., Sharan R., Shamir R., and Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res. 13 (2003) 773-780
10. Friedrich M., Rafi L., Tilgen W., Schmidt W., and Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J. Histochem. Cytochem. 46 (1998) 1335-1337
11. Friedrich M., Villena-Heinsen C., Tilgen W., Schmidt W., Reichrat J., and Axt-Fliedner R. Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res. 22 (2002) 1919-1924
12. Gu W., Shi X.-L., and Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 387 (1997) 819-823
13. Hughes J.D., Estep P.W., Tavazoie S., and Church G.M. Computational identification of cis-regulatory elements associated with groups of functionally related genes in Saccharomyces cerevisiae. J. Mol. Biol. 296 (2000) 1205-1214
14. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410
15. Jackson II R.S., Cho Y.J., Stein S., and Liang P. CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycle 6 (2007) 95-103
16. Kalo E., Buganim Y., Shapira K.E., Besserglick H., Goldfinger N., Weisz L., Stambolsky P., Henis Y.I., and Rotter V. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol. Cell. Biol. 27 (2007) 8228-8242
17. Kerner S.A., Scott R.A., and Pike J.W. Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc. Natl. Acad. Sci. USA 86 (1989) 4455-4459
18. Kim M.S., Fujiki R., Murayama A., Kitagawa H., Yamaoka K., Yamamoto Y., Mihara M., Takeyama K., and Kato S. 1{alpha},25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol. Endocrinol. 21 (2007) 334-342
19. Klucky B., Mueller R., Vogt I., Teurich S., Hartenstein B., Breuhahn K., Flechtenmacher C., Angel P., and Hess J. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 67 (2007) 8198-8206
20. Kogan I., Goldfinger N., Milyavsky M., Cohen M., Shats I., Dobler G., Klocker H., Wasylyk B., Voller M., Aalders T., et al. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. Cancer Res. 66 (2006) 3531-3540
21. Kommagani R., Caserta T.M., and Kadakia M.P. Identification of vitamin D receptor as a target of p63. Oncogene 25 (2006) 3745-3751
22. Kommagani R., Payal V., and Kadakia M.P. Differential regulation of vitamin D receptor (VDR) by the p53 family: p73-dependent induction of VDR upon DNA damage. J. Biol. Chem. 282 (2007) 29847-29854
23. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872
24. Lee M.G., Huh J.S., Chung S.K., Lee J.H., Byun D.S., Ryu B.K., Kang M.J., Chae K.S., Lee S.J., Lee C.H., et al. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene 25 (2006) 5807-5822
25. Lin J., Teresky A.K., and Levine A.J. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10 (1995) 2387-2390
26. Martoriati A., Doumont G., Alcalay M., Bellefroid E., Pelicci P.G., and Marine J.C. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. Oncogene 24 (2005) 1461-1466
27. Maruyama R., Aoki F., Toyota M., Sasaki Y., Akashi H., Mita H., Suzuki H., Akino K., Ohe-Toyota M., Maruyama Y., et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 66 (2006) 4574-4583
28. Matas D., Sigal A., Stambolski P., Milyavski M., Weisz L., Schwarts D., Goldfinger N., and Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO 20 (2001) 4163-4172
29. Menezes R.J., Cheney R.T., Husain A., Tretiakova M., Loewen G., Johnson C.S., Jayaprakash V., Moysich K.B., Salgia R., and Reid M.E. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 1104-1110
30. Moreno-Flores M.T., Martin-Aparicio E., Martin-Bermejo M.J., Agudo M., McMahon S., Avila J., Diaz-Nido J., and Wandosell F. Semaphorin 3C preserves survival and induces neuritogenesis of cerebellar granule neurons in culture. J. Neurochem. 87 (2003) 879-890
31. Murayama A., Kim M.S., Yanagisawa J., Takeyama K., and Kato S. Transrepression by a liganded nuclear receptor via a bHLH activator through co-regulator switching. EMBO J. 23 (2004) 1598-1608
32. Nakagawa K., Kawaura A., Kato S., Takeda E., and Okano T. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26 (2005) 429-440
33. Odom D.T., Zizlsperger N., Gordon D.B., Bell G.W., Rinaldi N.J., Murray H.L., Volkert T.L., Schreiber J., Rolfe P.A., Gifford D.K., et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 303 (2004) 1378-1381
34. Quandt K., Frech K., Karas H., Wingender E., and Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23 (1995) 4878-4884
35. Raval A., Tanner S.M., Byrd J.C., Angerman E.B., Perko J.D., Chen S.S., Hackanson B., Grever M.R., Lucas D.M., Matkovic J.J., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129 (2007) 879-890
36. Ripka S., Konig A., Buchholz M., Wagner M., Sipos B., Kloppel G., Downward J., Gress T., and Michl P. WNT5A-target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28 (2007) 1178-1187
37. Sahin M.O., Canda A.E., Yorukoglu K., Mungan M.U., Sade M., and Kirkali Z. 1,25 Dihydroxyvitamin D(3) receptor expression in superficial transitional cell carcinoma of the bladder: a possible prognostic factor?. Eur. Urol. 47 (2005) 52-57
38. Scian M.J., Stagliano K.E., Ellis M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., and Deb S. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 64 (2004) 7447-7454
39. Shaulian E., Zauberman A., Ginsberg D., and Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12 (1992) 5581-5592
40. Simon I., Barnett J., Hannett N., Harbison C.T., Rinaldi N.J., Volkert T.L., Wyrick J.J., Zeitlinger J., Gifford D.K., Jaakkola T.S., and Young R.A. Serial regulation of transcriptional regulators in the yeast cell cycle. Cell 106 (2001) 697-708
41. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1 (2001) 233-240
42. Soussi T., and Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 (2007) 303-312
43. Stambolsky P., Weisz L., Shats I., Klein Y., Goldfinger N., Oren M., and Rotter V. Regulation of AIF expression by p53. Cell Death Differ. 13 (2006) 2140-2149
44. Tabach Y., Brosh R., Buganim Y., Reiner A., Zuk O., Yitzhaky A., Koudritsky M., Rotter V., and Domany E. Wide-scale analysis of human functional transcription factor binding reveals a strong bias towards the transcription start site. PLoS ONE 2 (2007) e807
45. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
46. Wang S.H., Koenig R.J., Giordano T.J., Myc A., Thompson N.W., and Baker Jr. J.R. 1Alpha,25-dihydroxyvitamin D3 up-regulates Bcl-2 expression and protects normal human thyrocytes from programmed cell death. Endocrinology 140 (1999) 1649-1656
47. Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M., and Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 64 (2004) 8318-8327
48. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 67 (2007) 2396-2401
49. Weisz L., Oren M., and Rotter V. Transcription regulation by mutant p53. Oncogene 26 (2007) 2202-2211
50. Yasmin R., Williams R.M., Xu M., and Noy N. Nuclear import of the retinoid X receptor, the vitamin D receptor, and their mutual heterodimer. J. Biol. Chem. 280 (2005) 40152-40160
51. Zalcenstein A., Stambolsky P., Weisz L., Muller M., Wallach D., Goncharov T.M., Krammer P.H., Rotter V., and Oren M. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22 (2003) 5667-5676
52. Zhang X., Li P., Bao J., Nicosia S.V., Wang H., Enkemann S.A., and Bai W. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem. 280 (2005) 35458-35468
53. Zinser G., Packman K., and Welsh J. Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129 (2002) 3067-3076
54. Zinser G.M., Sundberg J.P., and Welsh J. Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis 23 (2002) 2103-2109